PriceTargets.com logo

Invivyd - IVVD Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $10.00
  • Forecasted Upside: 1,660.56%
  • Number of Analysts: 6
  • Breakdown:
  • 1 Sell Ratings
  • 2 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$0.57 As of 11/2/2026 10:37 AM ET
▼ -0.0137 (-2.36%)

This chart shows the closing price for IVVD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Invivyd Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IVVD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IVVD

Analyst Price Target is $10.00
▲ +1,660.56% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Invivyd in the last 3 months. The average price target is $10.00, with a high forecast of $10.00 and a low forecast of $10.00. The average price target represents a 1,660.56% upside from the last price of $0.57.

This chart shows the closing price for IVVD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 6 polled investment analysts is to hold stock in Invivyd. This rating has held steady since October 2025, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/11/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/9/2025
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 2 sell ratings
Ratings as of
11/7/2025
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
2/5/2026
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
5/6/2026
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
8/4/2026
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
10/3/2026
  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
11/2/2026

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 2 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
9/29/2026HC WainwrightReiterated RatingBuy ➝ Buy
9/14/2026BTIG ResearchReiterated RatingBuy ➝ Buy
9/8/2026Weiss RatingsUpgradeSell (E+) ➝ Sell (D-)
8/27/2026Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight
8/24/2026Weiss RatingsDowngradeSell (D-) ➝ Sell (E+)
8/18/2026HC WainwrightReiterated RatingBuy ➝ Buy
7/24/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
7/7/2026BTIG ResearchReiterated RatingBuy ➝ Buy
6/15/2026HC WainwrightReiterated RatingBuy ➝ Buy$10.00
6/9/2026BTIG ResearchReiterated RatingBuy ➝ Buy$10.00
6/1/2026BTIG ResearchReiterated RatingBuy ➝ Buy$10.00
5/18/2026BTIG ResearchReiterated RatingBuy ➝ Buy$10.00
5/14/2026HC WainwrightReiterated RatingBuy ➝ Buy
4/29/2026Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
2/26/2026BTIG ResearchReiterated RatingBuy ➝ Buy$10.00
1/21/2026BTIG ResearchReiterated RatingBuy ➝ Buy
12/29/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/22/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/22/2025BTIG ResearchInitiated CoverageBuy ➝ Buy$10.00
12/22/2025BTIG ResearchInitiated CoverageBuy ➝ Buy$10.00
12/15/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/8/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
12/2/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/26/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
11/25/2025D. Boral CapitalReiterated RatingBuy ➝ Hold
11/13/2025Zacks ResearchUpgradeStrong Sell ➝ Hold
10/31/2025HC WainwrightBoost TargetBuy ➝ Buy$5.00 ➝ $10.00
10/31/2025Weiss RatingsReiterated RatingSell (E+) ➝ Sell (E+)
10/15/2025Zacks ResearchDowngradeHold ➝ Strong Sell
10/8/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
10/6/2025D. Boral CapitalBoost TargetBuy ➝ Buy$1.00 ➝ $2.00
10/6/2025Cantor FitzgeraldInitiated CoverageOverweight$10.00
9/27/2025Weiss RatingsReiterated RatingSell (D-) ➝ Sell (D-)
8/27/2025HC WainwrightReiterated RatingBuy ➝ Buy$5.00
8/25/2025D. Boral CapitalLower TargetBuy ➝ Buy$3.00 ➝ $1.00
8/15/2025D. Boral CapitalLower TargetBuy ➝ Buy$9.00 ➝ $3.00
6/26/2025HC WainwrightReiterated RatingBuy ➝ Buy$5.00
6/26/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$9.00
5/28/2025HC WainwrightLower TargetBuy ➝ Buy$10.00 ➝ $5.00
5/16/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
3/26/2025HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
3/20/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
3/5/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
2/24/2025HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
2/24/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
2/4/2025HC WainwrightReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
2/3/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
1/27/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
1/10/2025D. Boral CapitalReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
11/21/2024D. Boral CapitalReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
11/20/2024Morgan StanleyLower TargetOverweight ➝ Overweight$9.50 ➝ $3.55
11/20/2024HC WainwrightLower TargetBuy ➝ Buy$15.00 ➝ $10.00
10/29/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
9/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
8/27/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
5/24/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00 ➝ $15.00
5/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00
4/5/2024GuggenheimUpgradeNeutral ➝ Buy$9.00
3/26/2024Morgan StanleyUpgradeEqual Weight ➝ Overweight$4.00 ➝ $10.00
3/25/2024HC WainwrightReiterated RatingBuy ➝ Buy$15.00
1/18/2024HC WainwrightBoost TargetBuy ➝ Buy$5.00 ➝ $15.00
12/19/2023Morgan StanleyUpgradeUnderweight ➝ Equal Weight$1.00 ➝ $4.00
8/14/2023HC WainwrightReiterated RatingBuy ➝ Buy$5.00
5/1/2023HC WainwrightInitiated CoverageBuy$5.00
3/27/2023Morgan StanleyLower TargetUnderweight$2.00 ➝ $1.00
1/24/2023Morgan StanleyLower TargetUnderweight$3.00 ➝ $2.00
9/14/2022Morgan StanleyInitiated CoverageUnderweight$3.00
(Data available from 11/2/2021 forward)

News Sentiment Rating

0.25 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/6/2026
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/6/2026
  • 2 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/5/2026
  • 3 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/5/2026
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
8/4/2026
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/3/2026
  • 7 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/3/2026
  • 2 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/2/2026

Current Sentiment

  • 2 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Invivyd logo
Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $0.57
Low: $0.59
High: $0.59

50 Day Range

MA: $0.79
Low: $0.58
High: $1.02

52 Week Range

Now: $0.57
Low: $0.53
High: $3.07

Volume

29,096 shs

Average Volume

4,025,109 shs

Market Capitalization

$167.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.2

Frequently Asked Questions

What sell-side analysts currently cover shares of Invivyd?

The following Wall Street sell-side analysts have issued stock ratings on Invivyd in the last year: BTIG Research, Cantor Fitzgerald, D. Boral Capital, HC Wainwright, Wall Street Zen, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for IVVD.

What is the current price target for Invivyd?

0 Wall Street analysts have set twelve-month price targets for Invivyd in the last year. Their average twelve-month price target is $10.00, suggesting a possible upside of 1,619.1%. BTIG Research has the highest price target set, predicting IVVD will reach $10.00 in the next twelve months. BTIG Research has the lowest price target set, forecasting a price of $10.00 for Invivyd in the next year.
View the latest price targets for IVVD.

What is the current consensus analyst rating for Invivyd?

Invivyd currently has 1 sell rating, 2 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in IVVD, but not buy more shares or sell existing shares.
View the latest ratings for IVVD.

What other companies compete with Invivyd?

Other companies that are similar to Invivyd include Adlai Nortye, Prime Medicine, Design Therapeutics, Aura Biosciences and Sinovac Biotech. Learn More about companies similar to Invivyd.

How do I contact Invivyd's investor relations team?

Invivyd's physical mailing address is 209 Church Street, New Haven, CT, 06510. The company's listed phone number is 781-819-0080 and its investor relations email address is [email protected]. The official website for Invivyd is www.invivyd.com. Learn More about contacing Invivyd investor relations.